Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer
Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.
Concurrent Chemoradiation/Atezolizumab Does Not Improve Survival in LS-SCLC
Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.
Acalabrutinib Earns FDA Priority Review in Untreated Mantle Cell Lymphoma
The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.
Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC
Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.
Adjuvant cCRT Improves Disease Control, But Increases AEs in Breast Cancer
Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.
Adding Bortezomib to Isa-Rd Elicits Durable Responses for Multiple Myeloma
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab Quadruplet Therapy Appears Well Tolerated in Multiple Myeloma
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab Quadruplet Therapy Shows PFS Advantage in Multiple Myeloma
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Biosignature Test May Predict Residual Risk Post-BCS/RT in HER2+ DCIS
Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.
Retrospective Radiotherapy in IBD Data May Warrant Prospective Research
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Retrospective Study Provides Initial Toxicity Data in Radiation-Treated IBD
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
HDP-101 Demonstrates Preliminary Efficacy in R/R Multiple Myeloma
Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.
177Lu-Dotatate Improves PFS in Recurrent Meningioma
Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.
Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma
UNITED is the first trial to assess MR-guided weekly adaptive on-line and real-time radiotherapy with clinical target volume margin reductions.
Support Groups May Help Manage Talquetamab-Related AEs in Multiple Myeloma
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
T-DXd Earns FDA Priority Review in Pretreated HER2-Low Breast Cancer
Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.
Starting at the Front Line in Metastatic Pancreatic Cancer As New Options Emerge, How Do You Select and Sequence?
Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.
Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma
A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.
Novel PET Imaging Agent Earns Fast Track Status for PSMA+ Prostate Cancer
In 2 clinical trials, 64Cu-SAR-bisPSMA was shown to be effective in detecting prostate cancer in patients with PSMA-positive lesions.
Hypofractionated RT After Mastectomy Is Noninferior to SOC in Breast Cancer
Hypofractionated postmastectomy radiotherapy was noninferior to standard radiation in patients who underwent a mastectomy.
Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer
Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.
Fertility Preservation Rates May Increase With Uterine Transposition in Pelvic Cancers
Uterine transposition is a newer tactic in the surgical oncology field to help preserve fertility for patients undergoing pelvic radiation.
IMRT Yields Similar QOL Vs Proton Therapy in Localized Prostate Cancer
Data show no differences in bowel function between treatment arms based on factors including age, disease risk, and fractionation schedule.
Neoadjuvant Therapy Trumps Surgery in NSCLC Debate
The University of Chicago goes against Northwestern Medicine to see who will be crowned the winner in the NSCLC debate.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Education on Post-Talquetamab Taste Changes May Help Manage Symptoms
Samantha Shenoy, NP, MSN, emphasized educating patients with multiple myeloma to help prepare them for potential taste alterations after talquetamab.
Dato-DXd: A Path to Potential Approval in NSCLC
Experts discussed the advancements in non–small cell lung cancer treatment and developments in both antibody-drug conjugate–based approaches and targeted therapies.
Neurological AEs Not Significantly Affiliated with Talquetamab Treatment
Samantha Shenoy, NP, MSN, indicated that neurological issues were not prevalent with talquetamab, despite occurrences with other bispecifics antibodies.
Optimizing AE Management Post CAR T-Cell Therapy in Multiple Myeloma
Experts spoke about the best practices for mitigating adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.
Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma
Experts in multiple myeloma discussed optimal dosing strategies for bispecific antibodies for patients with relapsed/refractory multiple myeloma.
